Table 1.
Clinical data from patient groups included in the study.
| Study Patients | n | Mean age (Range) | Gender | HLA DQ2/DQ8 | IgA anti- tTG/EMA | Marsh Criteria at Diagnosis | GFD | |
|---|---|---|---|---|---|---|---|---|
| Celiac Patients | uCD | 45 | 27.1 (4–76) | 36% males | + | + | II-III | No |
| GFD-CD | 15 | 34.2 (4–71) | 34% males | + | - | II-III | Yes | |
| Non Celiac Patients | I-controls | 15 | 42.1 (15–78) | 56% males | +/- | - (*A) | 0-I (M.M) | No |
| C-controls | 44 | 35.3 (6–81) | 41% males | - (*B) | - (*A) | 0 | No |
uCD (untreated celiac patients), GFD-CD (celiac patients treated with gluten free diet), I-controls (non celiac patients with other inflamed conditions) and C-controls (non-celiac disease patients without other inflamed conditions). IgA anti-tTG (Anti-tissue transglutaminase antibodies), EMA (Endomysium antibodies), GFD (Gluten free diet). M.M (mild mucosal alterations non compatibles with celiac disease). *A Serological test were performed only in genetically susceptible patients. *B Two patients had positive genetic susceptibility markers.